In February 2020, the FDA released a Table of Pharmacogenetic Associations which includes a list of medications for which they believe there is sufficient evidence to suggest an association between a genetic variant and the metabolism or therapeutic effect of a medication. In order to help health care providers utilize their patients’ genetic test results in a clinically useful way, we have added these gene-drug interactions to our precision decision software suite. To help health care providers to understand data that supports FDA recommendations, the TreatGx report and software now includes implications and recommendations for each of the added medications.